Institutional Biosafety Committee
Meeting Minutes

The meeting was called to order on 7/28/2026 at 11:30AM. A quorum was present. The meeting was held via Zoom and in-person (Melville Library – 5th Floor, Room W5530). The meeting was open.

Attendance
Voting Members Present:
Rachel Brownlee
Nicholas Carpino
Jeronimo Cello
Jorge Escobar
Hwan Kim
Christopher Kuhlow
Natalie Osorio
Alyssa Tuthill
Dafang Wang

Non-Voting Attendees, Staff and Guests Present:
Rebecca Dahl
Aimee Minton
Lu-Ann Kozlowski

Recording:
Erin Augello

Items
1. Meeting called to order at 11:40AM

2. Next meeting date and general announcements
The next meeting date is 8/25/2026. Dr. Kim surveyed the assembled group to assess any conflict of interest or quorum issues. Members should recuse themselves and leave the room or Zoom meeting during the review of a study on which they have a conflict of interest.

3. Review of minutes from last meeting

Review type: Full Committee Review
Action: Approved
Effective date: 7/28/2026
Vote: Total = 9 For = 9; Opposed = 0; Abstained = 0

4. Continuing reviews requiring IBC review
This section was reviewed and noted by the committee.

5. New studies for committee review

a. PROTO202600022 Therapies for kidney injury

PI:	Navjotsingh Pabla
Submission Type:	Initial Protocol
Safety Review Type:	Biosafety
Funding:	• Name: Stony Brook Foundation
Training:	PI and all laboratory staff have received appropriate training.
Applicable Section of the NIH Guidelines that the Research Falls Under	Section III-D
Containment Conditions:	BSL-2

Determination: Modifications Required
Modifications (If Applicable):
i. In section: BASIC INFORMATION
4. Please include a brief description of the rsNAM work.
ii. In section: FUNDING SOURCES
1. Please complete and attach a document illustrating relevant research activities (if from grant applications, attach the research strategy portion).
iii. In section: TISSUES, BLOOD OR BODILY FLUIDS
1. Mouse tissues can be used at BSL-1 and do not require BSL-2 containment unless they contain pathogens.
iv. In section: BACTERIA, YEASTS, FUNGI OR PARASITES
1. The biocontainment level for E. coli is BSL-1, unless pathogenic organisms are used.
v. In section: BIOHAZARDS
1. Mouse tissues and E. coli are BSL-1.
2. Please describe how the listed agents will be used for the proposed rsNAM work.
vi. In section: RECOMBINANT AND SYNTHETIC NUCLEIC ACIDS USAGE
1. Please review and clarify if the proposed activities belong to III-D.
vii. In section: RECOMBINANT AND SYNTHETIC NUCLEIC ACIDS WORK DESCRIPTION
2. Please edit the incomplete sentence.
The protocol indicates that a lentiviral vector is used. However, the PI answered "No" to Question 13, indicating that no HIV-derived lentiviral vector will be used. Please verify this response. If an HIV-derived lentiviral vector is used, Question 13 should be answered "Yes" and the corresponding section completed. If the lentiviral vector is derived from a source other than HIV, please answer Question 17 accordingly and complete the required information.
viii. In section: ANIMALS

4. Please provide IACUC protocol information.
ix. In section: GENETICALLY MODIFIED ANIMALS: DNA SOURCE
5. Change to "Yes" for use with lentivirus.
6. Change to "Yes".
Please clarify if lentiviruses are used in animals.
x. In section: RISK GROUP AND CONTAINMENT PRACTICES
1. The response to the question regarding the highest Risk Group should be reviewed. Human cell lines are generally considered Risk Group 2 materials for institutional biosafety purposes. If the study uses an HIV-derived lentiviral vector, the highest Risk Group is RG3. If only a non-HIV lentiviral vector is used, the highest Risk Group is RG2. Please revise the response accordingly after clarifying the type of lentiviral vector used.
Effective Date: 7/28/2026
Project Expiration: 7/27/2027
Votes:

For:	9
Against:	0
Recused:	0
Absent:	1
Abstained:	0

b. PROTO202600024 rDNA

PI:	Lina Carlini
Submission Type:	Initial Protocol
Safety Review Type:	Biosafety
Funding:	• Name: Stony Brook Foundation, Grant Office ID: 1190066, Funding Source ID: start-up • Name: Stony Brook University, Grant Office ID: 106416
Training:	PI and all laboratory staff have received appropriate training.
Applicable Section of the NIH Guidelines that the Research Falls Under	Section III-D
Containment Conditions:	BSL-2

Determination: Approved
Modifications (If Applicable):
i. In section: BASIC INFORMATION
4. Please summarize the proposed rsNAM work and its goals.
ii. In section: PROTOCOL TEAM MEMBERS
1. Please indicate the PI's role and involvement with procedures.
iii. In section: FUNDING SOURCES
1. Please complete.
iv: In section: BIOSAFETY SUMMARY
1. Need to select Primary Cells or Cell Lines & Bacteria, Yeasts, Fungi, or Prions in this section and complete information in corresponding sections.
v. In section: EXPOSURE ASSESSMENT AND PROTECTIVE EQUIPMENT

5. Please update the BSC certification date.

Effective Date: 7/31/2026
Project Expiration: 7/30/2027
Votes:

For:	9
Against:	0
Recused:	0
Absent:	1
Abstained:	0

c. SPROTO202600000002 RNA virus replication and pathogenesis.

PI:	Kenneth Stapleford
Submission Type:	Initial Protocol
Safety Review Type:	Biosafety
Funding:	• Name: National Institute of Allergy & Infectious Disease, Grant Office ID: FP00016165, Funding Source ID: 7R21AI194469-02 • Name: National Institute of Allergy & Infectious Disease, Grant Office ID: FP00016165, Funding Source ID: 7R01AI162774-06
Training:	PI and all laboratory staff have received appropriate training.
Applicable Section of the NIH Guidelines that the Research Falls Under	Section III-D
Containment Conditions:	BSL-3

Determination: Modifications Required
Modifications (If Applicable):
i. In section: BASIC INFORMATION
4. Summary of research is too long. The first two paragraphs are sufficient.
PI should correct the BSL designations throughout the protocol. Non-human mammalian cell lines and E. coli K-12 strains are classified as BSL-1 host systems. Their use under BSL-2 or BSL-3 containment for specific experiments does not change their original BSL classification. In addition, please replace “sacrifice” with “euthanize”
ii. In section: FUNDING SOURCES
1. Please attach documents illustrating the relevant rsNAM work proposed in each application (copies of research strategy from grant applications).
iii. In section: BACTERIA, YEASTS, FUNGI OR PARASITES
1. E. coli are handled under BSL1.
iv. In section: RECOMBINANT AND SYNTHETIC NUCLEIC ACIDS WORK DESCRIPTION
1. The use of mice is not recombinant nucleic acid work and could be omitted from this section unless it is directly relevant to the recombinant constructs.

2. The PI lists Cas9 as a reporter. Cas9 is not a reporter gene; it is a CRISPR-associated endonuclease. It should be listed separately from the reporter genes.
3. Identify the species of origin for Cas9 (typically Streptococcus pyogenes, unless another ortholog is used).
6. A brief description of each vector or at least its intended use (e.g., mammalian expression vector, infectious clone backbone, bacterial expression vector, etc.) should be included.
9. Please revise. The response "None" is inconsistent with the remainder of the protocol. The protocol clearly states that viral proteins, GFP, mCherry, luciferase, Cas9, and viral glycoproteins will be expressed.
v. In section: ANIMALS
4. Missing IACUC protocol information. If submitted, please select “Pending Approval.”
vi. In section: EXPOSURE ASSESSMENT AND PROTECTIVE EQUIPMENT
1. PI should expand this section to describe the consequences of exposure for all viruses used in the protocol, as the current description is incomplete. In addition, please address the potential consequences of exposure to human cell lines, primary human cells, and human blood, including the potential risk of bloodborne pathogen exposure.
4. For any new BSCs in the BSL2 laboratory, please submit an amendment with new certificates. If PI wishes to use any common BSCs in LS or CMM, please update this information as well.
vii. In section:DUAL USE RESEARCH OF CONCERN
The PI identifies CHIKV and WNV as Category 1 biological agents and selects the Category 1 experiment categories of increasing transmissibility and increasing virulence. However, the accompanying explanation states that the mutations being studied are naturally occurring and therefore are unlikely to alter virus biology.
If the proposed experiments are not reasonably anticipated to increase transmissibility or virulence, then perhaps the Category 1 experiment categories should not have been selected. On the other hand, if those selections are intentional, then the explanation may need to better justify why the research should or should not be considered Category 1 research under the current DURC/PEPP policy. Additional clarification is required with specific risk mitigation plans.
In addition, the PI states that Semliki Forest virus is not manipulated in the laboratory and therefore would not result in any of the nine outcomes. However, Semliki Forest virus is not listed among the materials subject to Category 1 review. Please clarify.
Effective Date: 7/31/2026
Project Expiration: 7/30/2027
Votes:

For:	9
Against:	0
Recused:	0
Absent:	1
Abstained:	0

6. Amendments requiring IBC review
None
7. Review of incidents
None

8. Review of other agenda items

None

9. Inspection results
All inspections and responses were summarized by Mr. Kuhlow and reviewed and noted by the committee.

10. Discussion items/readings (major and minor points of order)
None

11. Meeting adjourned at **12:32PM**